´Ù¹ß°ñ¼öÁ¾¿¬±¸È¸ 2021 »ó¹Ý±â KMMWP workshop & Àӻ󿬱¸¸ðÀÓ : 2021-06-26±³À°ÀÏÀÚ : 2021-06-26
±³À°Àå¼Ò : THE K HOTEL , °¡¾ß±ÝȦ(2F)
±³À°ÁÖÁ¦ :
2021 »ó¹Ý±â KMMWP workshop & Àӻ󿬱¸¸ðÀÓÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´Ù¹ß°ñ¼öÁ¾¿¬±¸È¸
´ã´çÀÚ : ¼È¿Áø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ :
kmmwp_office@naver.com ±³À°Á¾·ù : ³»°ú, Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀοø : 50¸í
Èñ¸ÁÆòÁ¡ : 4Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 4 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í Äڷγª 19·Î »çÀü Âü¿© µî·ÏÀÌ Á¶±â ¸¶°¨ µÉ ¼ö ÀÖ½À´Ï´Ù.
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06-26 °¡¾ß±ÝȦ 09:30~10:00 Cytogenetic testing in multiple myeloma ±èÇö¿µ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 06-26 °¡¾ß±ÝȦ 10:00~10:30 Recent studies and trends with next generation flow in multiple myeloma Ȳ»ó¹Ì(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06-26 °¡¾ß±ÝȦ 10:30~11:00 Targeted next-generation sequencing in multiple myeloma ½Å»õ¾Ï(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06-26 °¡¾ß±ÝȦ 11:10~11:40 Emerging agents in the treatment of multiple myeloma ÀÌÁØÈ£(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 06-26 °¡¾ß±ÝȦ 11:40~12:10 Evaluation and management of major adverse events of CAR-T cell therapy À±»óÀº(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 06-26 °¡¾ß±ÝȦ 12:10~12:40 Safety issues of upcoming novel agents (Selinexor, Belantamab mafodotin etc.) Á¶Àçö(¿ï»êÀÇ´ë)
±³À°½Ã°£ 06-26 °¡¾ß±ÝȦ 13:30~14:00 Experiences of phase III clinical trial for Korean multiple myeloma patients (KMM 163) ½ÅÈ£Áø(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 06-26 °¡¾ß±ÝȦ 14:00~14:30 How to design a more successful clinical study in Korea ÀÌÈ£¼·(°í½ÅÀÇ´ë)